跳至主要内容
临床试验/ACTRN12613000520730
ACTRN12613000520730尚未招募不适用

The effect of adjuvant therapy with aspirin on relapse prevention of hepatocellular carcinoma after curative resection: A prospective randomized controlled trial

Estern hepatobiliary surgery hospital0 个研究点目标入组 120 人开始时间: 2013年5月10日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 70 Years(—)
性别
All

入选标准

  • Patients whose age ranged from 18 to 70 years, with histologically proven heptocellular carcinoma, and who underwent curative hepatectomy with less than 50% of the liver and with a tumor-free resection margin greater than 1 cm; Child-Pugh class A; normalized hepatic function (glutamic pyruvic transaminase/glutamic oxaloacetic transaminase (GPT/GOT) less than or equal to 2 times the upper normal limit; total serum bilirubin less than 34.2 micro mol/L); normal renal function and hematological parameters (serum creatinine less than 132 micro mol/L; white blood cell (WBC) count greater than or equal to 2.5×109/L; platelet count (PLT) greater than or equal to 40×109/L); life expectancy longer than 6 months.

排除标准

  • Prior therapy with chemotherapy, allergy or history of severe adverse reactions to aspirin, the other region metastases, and malignant tumors in other regions of the body over the previous two years; peripheral neuropathy, history of central nervous system diseases, abnormal electrocardiogram findings, psychiatric disorders; severe cardiac, metabolic and/or infectious diseases; active peptic ulcer disease requiring treatment, absorption disorders; Pregnant or lactating females.

研究者

发起方
Estern hepatobiliary surgery hospital

相似试验